Stock events for SCYNEXIS, Inc. (SCYX)
Several events have impacted SCYNEXIS, Inc.'s stock price in the past six months. SCYNEXIS announced a $40.0 million private placement and completed the transformative acquisition of PXL-770 on March 31, 2026. On March 4, 2026, SCYNEXIS reported its Full Year 2025 Financial Results and provided a corporate update. On February 26, 2026, SCYNEXIS announced the first participants were dosed in a Phase 1 trial of intravenous SCY-247. On January 28, 2026, the company announced presentations highlighting the potent antifungal activity of its second-generation fungerp, SCY-247, against drug-resistant fungi. Historically, SCYNEXIS shares have tended to move lower in the immediate aftermath of earnings reports.
Demand Seasonality affecting SCYNEXIS, Inc.’s stock price
Direct information regarding demand seasonality for SCYNEXIS, Inc.'s specific products and services is not explicitly provided. However, there is a tool available to analyze the mean and median monthly returns for SCYX to identify seasonal patterns in the stock's performance.
Overview of SCYNEXIS, Inc.’s business
SCYNEXIS, Inc. is a biotechnology company focused on developing therapies for difficult-to-treat infections, operating in the Healthcare sector. The company's primary focus is on its proprietary triterpenoid antifungal platform, known as "fungerps." Its major products include BREXAFEMME (ibrexafungerp), SCY-247, and PXL-770.
SCYX’s Geographic footprint
SCYNEXIS, Inc. is headquartered in Jersey City, New Jersey, United States, with drug development efforts primarily focused on the United States market.
SCYX Corporate Image Assessment
Information specifically detailing SCYNEXIS, Inc.'s brand reputation is not readily available. The available information focuses on corporate and product development news.
Ownership
The ownership structure of SCYNEXIS (SCYX) stock is a mix of institutional, retail, and individual investors. Approximately 18.47% to 22.17% of the company's stock is owned by Institutional Investors, 5.93% by Insiders, and 71.90% by Public Companies and Individual Investors (retail investors). Major institutional owners include Avidity Partners Management LP, Goldman Sachs Group Inc, and Vanguard Group Inc.
Ask Our Expert AI Analyst
Price Chart
$1.11
